EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+9.77%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$133M
AUM Growth
+$133M
(-10%)
Cap. Flow
-$15.9M
Cap. Flow
% of AUM
-11.94%
Top 10 Holdings %
Top 10 Hldgs %
37.04%
Holding
83
New
23
Increased
12
Reduced
17
Closed
24
Top Buys
| 1 |
Humana
HUM
|
$4.58M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$4.22M |
| 3 |
Arvinas
ARVN
|
$4.19M |
| 4 |
Boston Scientific
BSX
|
$3.62M |
| 5 |
Soleno Therapeutics
SLNO
|
$3.47M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$6.55M |
| 2 |
TG Therapeutics
TGTX
|
$4.86M |
| 3 |
Align Technology
ALGN
|
$4.76M |
| 4 |
Cigna
CI
|
$4.23M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Sector Composition
| 1 | Healthcare | 98.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $6.77M | 5.09% | 246,700 +35,700 | +17% | +$980K |
|
2
Eli Lilly
LLY
$657B
| $6.37M | 4.78% | 8,247 -2,200 | -21% | -$1.7M |
|
3
Geron
GERN
$893M
| $5.62M | 4.22% | 1,561,152 +656,026 | +72% | +$2.36M |
|
|
4
Humana
HUM
$36.5B
| $4.58M | 3.44% | +18,066 | New | +$4.58M |
|
5
Guardant Health
GH
$8.41B
| $4.52M | 3.39% | 147,800 +58,000 | +65% | +$1.77M |
|
6
Relay Therapeutics
RLAY
$619M
| $4.46M | 3.35% | 1,083,487 +668,858 | +161% | +$2.76M |
|
7
Disc Medicine
IRON
$2.07B
| $4.38M | 3.29% | 69,072 +4,556 | +7% | +$289K |
|
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.22M | 3.17% | +318,900 | New | +$4.22M |
|
|
9
Arvinas
ARVN
$568M
| $4.19M | 3.15% | +218,700 | New | +$4.19M |
|
10
Structure Therapeutics
GPCR
$1.11B
| $4.12M | 3.1% | 151,965 +31,800 | +26% | +$862K |
|
11
Intuitive Surgical
ISRG
$170B
| $3.88M | 2.91% | 7,427 | – | – |
|
12
Apellis Pharmaceuticals
APLS
$3.48B
| $3.81M | 2.86% | 119,467 +19,100 | +19% | +$609K |
|
13
Bristol-Myers Squibb
BMY
$96B
| $3.69M | 2.77% | 65,200 -12,800 | -16% | -$724K |
|
|
14
Boston Scientific
BSX
$156B
| $3.62M | 2.72% | +40,500 | New | +$3.62M |
|
15
Natera
NTRA
$23.1B
| $3.55M | 2.67% | 22,450 | – | – |
|
|
16
Soleno Therapeutics
SLNO
$3.6B
| $3.47M | 2.61% | +77,285 | New | +$3.47M |
|
17
Scholar Rock
SRRK
$3.14B
| $3.35M | 2.51% | 77,439 -55,600 | -42% | -$2.4M |
|
18
Nuvalent
NUVL
$5.52B
| $3.19M | 2.39% | 40,580 +20,635 | +103% | +$1.62M |
|
19
Cytokinetics
CYTK
$4.23B
| $3.1M | 2.33% | 65,883 +7,300 | +12% | +$343K |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $2.77M | 2.08% | 31,800 -4,900 | -13% | -$427K |
|
21
Gilead Sciences
GILD
$140B
| $2.74M | 2.06% | 29,700 -20,300 | -41% | -$1.88M |
|
22
Summit Therapeutics
SMMT
$17.6B
| $2.33M | 1.75% | +130,412 | New | +$2.33M |
|
|
CNTA
23
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.31M | 1.73% | 137,716 -436 | -0.3% | -$7.3K |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $2.18M | 1.63% | 81,473 +21,573 | +36% | +$576K |
|
25
Janux Therapeutics
JANX
$1.37B
| $2.15M | 1.61% | +40,123 | New | +$2.15M |
|